Sime Armoyan Purchases 17,600 Shares of Knight Therapeutics Inc. (TSE:GUD) Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan bought 17,600 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of C$5.48 per share, for a total transaction of C$96,488.48.

Knight Therapeutics Price Performance

TSE GUD opened at C$5.55 on Friday. The company has a market capitalization of C$561.38 million, a PE ratio of -18.53, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The business’s fifty day moving average is C$5.53 and its 200 day moving average is C$5.56. Knight Therapeutics Inc. has a fifty-two week low of C$5.09 and a fifty-two week high of C$6.23.

Analyst Ratings Changes

Separately, Raymond James upgraded Knight Therapeutics to a “moderate buy” rating in a research report on Friday, November 15th.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.